LungLife AI Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Paul Pagano

Chief executive officer

US$316.6k

Total compensation

CEO salary percentage93.4%
CEO tenure5.2yrs
CEO ownership0.09%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Pagano's remuneration changed compared to LungLife AI's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$317kUS$296k

-US$5m

Sep 30 2023n/an/a

-US$6m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$7m

Dec 31 2022US$335kUS$275k

-US$8m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$356kUS$230k

-US$7m

Compensation vs Market: Paul's total compensation ($USD316.60K) is below average for companies of similar size in the German market ($USD468.04K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


CEO

Paul Pagano (39 yo)

5.2yrs

Tenure

US$316,595

Compensation

Dr. Paul Pagano, Ph.D. has been Chief Scientific Officer at LungLife AI, Inc. since October 2019. Dr. Pagano serves as Chief Executive Officer of LungLife AI, Inc and serves as Executive Director since Jul...


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 19:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LungLife AI, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Adam BarkerGoodbody Stockbrokers
Andrew WhitneyInvestec Bank plc (UK)
Jens LindqvistInvestec Bank plc (UK)